Gain Therapeutics Newsroom

Gain Therapeutics Analyst Ratings

BenzingaOct 9 19:15

H.C. Wainwright Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $8

Futu NewsOct 9 18:31

Maxim Group Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $5

Futu NewsOct 2 00:31

Gain Therapeutics Analyst Ratings

BenzingaOct 1 18:58

H.C. Wainwright Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $8

Futu NewsOct 1 18:31

BTIG Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $10

Futu NewsOct 1 06:32

Maxim Group Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $5

Futu NewsSep 21 01:32

Optimistic Buy Rating for Gain Therapeutics' GT-02287 Based on Promising Parkinson's Disease Treatment Potential

TipRanksSep 21 00:38

Maxim Group Maintains Gain Therapeutics(GANX.US) With Buy Rating, Announces Target Price $5

Futu NewsSep 4 08:32

Gain Therapeutics Analyst Ratings

BenzingaSep 3 19:34

HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target

BenzingaSep 3 19:33

H.C. Wainwright Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $8

Futu NewsSep 3 18:31

Oppenheimer Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $8

Futu NewsAug 31 08:32

Gain Therapeutics Price Target Announced at $8.00/Share by Oppenheimer

Dow JonesAug 14 20:14

Gain Therapeutics Analyst Ratings

BenzingaAug 14 20:06

Gain Therapeutics Analyst Ratings

BenzingaAug 10 05:17

Chardan Capital Maintains Buy on Gain Therapeutics, Maintains $6 Price Target

BenzingaAug 10 05:16

Buy Rating Affirmed for Gain Therapeutics on GT-02287 Clinical Progress and Robust Financial Health

TipRanksAug 9 20:04

Gain Therapeutics Analyst Ratings

BenzingaJul 11 18:25

HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target

BenzingaJul 11 18:25